Day

July 2, 2017
Issue 22 of Multiple Myeloma Research Review. Highlights include: •   Benefits of low dose lenalidomide in relapsed/refractory MM. •   Network meta-analysis: treatment outcomes in relapsed/refractory MM. •   Improved outcomes for patients treated a speciality MM clinics. •   Real world benefits of bortezomib regimens for non-transplant eligible MM. Download here
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand